Leighl, Natasha B <br/><br/>
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Jun 2006 
 - 327-32 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2006.02.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Small Cell--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Salvage Therapy<br/>Survival Rate<br/>Vincristine--administration & dosage